Autologous engineered T cell receptor therapy in advanced cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Autologous engineered T cell receptor therapy in advanced cancer

Published:2023-12-15 Issue:3 Volume:19 Page:
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Tsimberidou Apostolia M.¹^ORCID,Baysal Mehmet A.¹^ORCID,Chakraborty Abhijit¹^ORCID,Andersson Borje S.²^ORCID

Affiliation:

1. Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

2. Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Funder

University of Texas MD Anderson Cancer Center

National Cancer Institute

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2023.2290356

Reference36 articles.

1. T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors

2. The Prioritization of Cancer Antigens: A National Cancer Institute Pilot Project for the Acceleration of Translational Research

3. TCR-engineered T cells to treat tumors: Seeing but not touching?

4. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells

5. Treatment of Metastatic Melanoma with Autologous CD4+ T Cells against NY-ESO-1

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP